the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |

View All Categories

Mental Disease Therapeutic Market Research

 

Global Information, Inc. offers market intelligence on every topic in the Mental Disease Therapeutic, including, but not limited to market trend on Therapeutic of: Antidepressant; Psychiatric Disorder; Insomnia; Neurodegenerative; Antianxiety; Antipsychotics; Alzheimer; Psychiatry; PTSD.

We offer market research, industry forecasts, and business analysis in the Mental Disease Therapeutic as well as other vertical industries. GII sells reports, databases, newsletters and annual information services that provide the latest market data, such as industry forecasts, projections, trends, market shares, research and development, sales and marketing strategies, and competitive analysis. The easiest way to find out if we have the information you need is to contact us right now. We are open 24 hours a day, 5 days a week with multiple language support. Please see our Contact page to see which office is open right now.

 

Reports

Undiagnosed Sleep Disorder Market Offers Growth Opportunities
Published : 2008/04
The report analyzes the sleep disorder treatment market. The focus is on OSA and insomnia treatment products. The report also profiles the major companies, with a discussion of their key business strategies. ...

Central Nervous System Alzheimer Disease
Published : 2008/03
Life Science Analytics' , Central Nervous System Alzheimer Disease contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the late ...

Central Nervous System Anxiety
Published : 2008/03
Life Science Analytics' , Central Nervous System Anxiety contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news an ...

Central Nervous System Attention Deficit Disorder with Hyperactivity
Published : 2008/03
Life Science Analytics' , Central Nervous System Attention Deficit Disorder with Hyperactivity contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as w ...

Central Nervous System Dementia
Published : 2008/03
Life Science Analytics' , Central Nervous System Dementia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news a ...

Central Nervous System Depression
Published : 2008/03
Life Science Analytics' , Central Nervous System Depression contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news ...

Central Nervous System Epilepsy
Published : 2008/03
Life Science Analytics' , Central Nervous System Epilepsy contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news a ...

Central Nervous System Headache
Published : 2008/03
Life Science Analytics' , Central Nervous System Headache contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news a ...

Central Nervous System Insomnia or Sleep Disorders
Published : 2008/03
Life Science Analytics' , Central Nervous System Insomnia or Sleep Disorders contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary o ...

Central Nervous System Memory Impairment
Published : 2008/03
Life Science Analytics' , Central Nervous System Memory Impairment contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the late ...

Central Nervous System Migraine
Published : 2008/03
Life Science Analytics' , Central Nervous System Migraine contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news a ...

Central Nervous System Multiple Sclerosis
Published : 2008/03
Life Science Analytics' , Central Nervous System Multiple Sclerosis contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the lat ...

Central Nervous System Neuropathy
Published : 2008/03
Life Science Analytics' , Central Nervous System Neuropathy contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news ...

Central Nervous System Pain
Published : 2008/03
Life Science Analytics' , Central Nervous System Pain contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and d ...

Central Nervous System Parkinson Disease
Published : 2008/03
Life Science Analytics' , Central Nervous System Parkinson Disease contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the late ...

Central Nervous System Psychotic Disorders
Published : 2008/03
Life Science Analytics' , Central Nervous System Psychotic Disorders contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the la ...

Central Nervous System Schizophrenia
Published : 2008/03
Life Science Analytics' , Central Nervous System Schizophrenia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest n ...

Central Nervous System Seizures
Published : 2008/03
Life Science Analytics' , Central Nervous System Seizures contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news a ...

Central Nervous System Stroke
Published : 2008/03
Life Science Analytics' , Central Nervous System Stroke contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and ...

Pipeline and Commercial Insight: Alzheimer's Disease - Scenario forecasts reveal vast market potential
Published : 2008/03
With the AD market entering a pivotal phase, Datamonitor has conducted several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. H ...

Peripheral Neuropathy and Neuropathic Pain, 2008
Published : 2008/01
This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prev ...

U.S. Neurostimulation Devices Market
Published : 2008/01
This research service analyzes the U.S. neurostimulation market from 2003 to 2013. ...

Stakeholder Insight: Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics
Published : 2007/12
This report provides Parkinson's Disease Stakeholder Insight Market Research, Trends, Analysis. ...

Alzheimer's Disease Market analysis and forecasts, 2007-2012, 2017 & 2022
Published : 2007/10
This report provides Alzheimer's Disease Market Research, Trends, Analysis. ...

Does the Treatment of Huntington's Disease Represent a Commercial Opportunity?
Published : 2007/08
Huntington' s disease (HD) is a genetic neurological disorder characterized by uncontrolled body movements and cognitive dysfunction. No drugs are approved to treat the disorder, leaving a high level of unmet need. ...

Advances in Neurostimulators
Published : 2007/06
This research service analyses the critical trends and advancements made in neurostimulators. ...

CNS Market Trends, 2007 to 2010
Published : 2007/06
The global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55.5 billion in 2005, a year-on-year increase of 6.6%. ...

Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market
Published : 2007/06
Novel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, gen ...

Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
Published : 2007/06
Ambien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to rec ...

Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
Published : 2007/06
The dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva' s Copaxone (glatiramer acetate), and the recent relaun ...

Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
Published : 2007/06
This report provides comprehensive information on the neurodegenerative diseases; Parkinson' s Disease, Alzheimer' s Disease, Multiple Sclerosis and Neuropathic pain. ...

Rimonabant: The first of the Cannabinoid blockbusters
Published : 2007/06
The report provides in-depth market analysis for current and potential products. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research and highlighting new indications. ...

US Markets for Varicose Vein Treatment Devices 2007
Published : 2007/06
This market consists of endovenous laser ablation, endovenous radio frequency ablation, surgical stripping, phlebectomy, and sclerotherapy procedures for varicose veins ...

European Neurophysiological Monitors Market
Published : 2007/04
This research service analyses the neurophysiological monitors market in Europe; identifies the drivers, restraints and challenges in the market, provides revenue forecasts and strategic recommendations for growth. ...

Asia Pacific Markets for Interventional Neuroradiology Transcatheter Embolization and Occlusion devices 2006 (China, India, Australia, South Korea, Thailand, Taiwan, Malaysia)
Published : 2007/01
In 2005, the Asia Pacific interventional neuroradiology (INR) transcatheter embolization and occlusion (TEO) market was valued at over $46 million. ...

The Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007
Published : 2007/01
This report provides an insight into the neurodegenerative market, neurotherapeutic drugs currently available, and upcoming products. ...

Atypical Antipsychotics: Life-Cycle Management and Future Trends
Published : 2006/12
The $15 billion antipsychotics market will be hard hit by generics of nearly all the most frequently prescribed atypicals and by a dearth of breakthrough therapies in the pipeline. Overall market decline will be signifi cant by 2015, but current market le ...

Expanding a Brand: Statins and PPAR-Gamma Agonists to Treat Neurological Disease
Published : 2006/12
The repositioning of agents to treat neurodegenerative disorders represents a signifi cant opportunity for companies that have products in highly competitive markets. Although the value of neurodegenerative markets is small by comparison, the signifi cant ...

Industry Analysis--Changing Dynamics in Worldwide Psychiatric Franchises
Published : 2006/12
The treatment of psychiatric diseases is hardly straightforward; patients often try many different drug regimens and combinations in order to identify an optimal course of therapy. ...

Pricing and Reimbursement Issues in Psychiatry
Published : 2006/12
Compared with many other disease areas (e.g., cancer, immune diseases), the costs of drug therapy for psychiatric disorders are relatively modest. ...

Pipeline Insight: Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth
Published : 2006/09
Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market will grow until 2011, when revenues will peak at $6.6 billion. ...

How Will Deep Brain Stimulation Affect Neurological and Psychiatric Drug Markets?
Published : 2006/08
Deep brain stimulation (DBS) is currently approved only to treat Parkinson's disease and Parkinson-like symptoms; however, clinical trials are under way for DBS in several other neurological and psychiatric disorders. ...

Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome - Reformulations set to drive near-term growth
Published : 2006/08
Despite affecting a large number of individuals, there are currently no treatments capable of curing either Parkinson's disease or Restless Legs Syndrome. ...

Sleep Disorders: Promotion and Awareness Will Drive Market Growth
Published : 2006/08
In this report, we focus on the four sleep disorders thought to have major significance for physical and mental health: insomnia, narcolepsy, restless legs syndrome (RLS), and sleep apnea. ...

European Antidepressants Markets
Published : 2006/06
This Frost & Sullivan research service titled European Antidepressants Markets provides a detailed analysis of the antidepressants markets, with a description of key market drivers and restraints. An analysis of the product pipelines of leading companies ...

Schizophrenia Market: Novel Agents May Establish New Leaders
Published : 2006/05
Schizophrenia is a complex disease whose biology is not completely understood, a reality that presents a major hurdle to companies developing new therapies for schizophrenia. ...

Pipeline Insight: Anxiety Disorders - A decade of declining revenues
Published : 2006/03
The global anxiety disorders market is set to decline from $4.5 billion in 2006 to $2.6 billion by 2015 (CAGR 2006-15 -6.0%). ...

Stakeholder Insight: Major Depressive Disorder - Duloxetine - Fulfilling An Unmet Need?
Published : 2006/03
Major Depressive Disorder (MDD) is estimated to affect over 34 million individuals yearly across the seven major markets. ...

Stakeholder Insight: Cognitive Impairment in Schizoaffective Disorder - Inevitable or Treatable?
Published : 2005/10
Cognitive impairment is regarded as a core deficit of schizophrenia; the primary unmet need is the availability of an effective drug for the treatment of cognitive impairment in schizophrenia (CIS) ...

Emotional and Behavioral Disorders in Children and Adolescents
Published : 2005/09
The emotional and behavioral disorder drug market is changing as a result of the heightened awareness of these diseases in young children and adolescents and the use of drugs dedicated to controlling these problems. ...

Annual Information Services

The Outlook for Pharmaceuticals in Latin America to 2012
Each country report provides a comprehensive analysis of the pharmaceutical market, including five-year market forecasts. For each country you will receive 4 completely updated reports sent quarterly, plus comprehensive report sent annually. ...


Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.